ArticleThe Journal of pharmacology and experimental therapeutics2026
Xylazine's κ relatively potent opioid agonist activity is not shared with other US Food and Drug Administration-approved α
Xi-Ping Huang, Brian E Krumm, Madigan L Bedard, Zoe A McElligott, Bryan L Roth
Abstract read
In one paragraphArticle in The Journal of pharmacology and experimental therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
5 authors.
Xi-Ping HuangDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina; National Institute of Mental Health Psychoactive Drug Screening Program, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina.
Brian E KrummDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina.
Madigan L BedardBowles Center for Alcohol Studies, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina.
Zoe A McElligottDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina; Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina; Department of Psychiatry, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina.
Bryan L RothDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina; National Institute of Mental Health Psychoactive Drug Screening Program, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina; Division of Chemical Biology and Medicinal Chemistry, EShelman School of Pharmacy, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina. Electronic address: bryan_roth@med.unc.edu.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Indexed as
Adrenergic alpha-2 Receptor AgonistsAnalgesics, OpioidReceptors, Opioid, kappaXylazineAnimalsCHO CellsCricetulusHumansReceptors, Adrenergic, alpha-2United StatesUnited States Food and Drug AdministrationAdrenergic alpha-2 Receptor AgonistsAnalgesics, OpioidReceptors, Adrenergic, alpha-2Receptors, Opioid, kappaXylazineGPCROverdoseSide effectsXylazineα2-adrenergic receptorκ-opioid receptor
Identifiers
PMID42472543
PMCPMC13632507
What OpenQuestion holds
Textmetadata
Read underepoch 390